Beneski Benjamin Machinas 4
4 · Allogene Therapeutics, Inc. · Filed Apr 2, 2026
Research Summary
AI-generated summary of this filing
Allogene (ALLO) SVP/CTO Beneski Sells 2,867 Shares
What Happened
- Beneski Benjamin Machinas, SVP and Chief Technical Officer of Allogene Therapeutics (ALLO), sold 2,867 shares on 2026-03-31 at $2.50 per share, generating $7,168 in proceeds. The filing classifies the transaction as a sale (S).
Key Details
- Transaction date and price: 2026-03-31 — 2,867 shares sold at $2.50 each.
- Total value: $7,168.
- Shares owned after transaction: Not reported in this Form 4.
- Footnote: The sale was a "sell to cover" to satisfy tax withholding on vested restricted stock units, mandated by the issuer's equity plan (footnote F1). This is not a discretionary trade by the reporting person.
- Filing: Form 4 filed 2026-04-02; this filing is within the typical two-business-day SEC reporting window (timely).
Context
- Sell-to-cover transactions are routine administrative sales to pay taxes on vesting equity and generally do not indicate an insider's view of the company's prospects.
Insider Transaction Report
Form 4
Beneski Benjamin Machinas
SVP, Chief Technical Officer
Transactions
- Sale
Common Stock
[F1]2026-03-31$2.50/sh−2,867$7,168→ 195,338 total
Footnotes (1)
- [F1]Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Signature
/s/Earl Douglas, Attorney-in-Fact|2026-04-02